Alps Advisors Inc. Takes Position in Dr.Reddy’s Laboratories Ltd (RDY)

Share on StockTwits

Alps Advisors Inc. purchased a new position in Dr.Reddy’s Laboratories Ltd (NYSE:RDY) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,338 shares of the company’s stock, valued at approximately $616,000.

Several other institutional investors have also made changes to their positions in the business. Private Capital Group LLC grew its position in Dr.Reddy’s Laboratories by 209.2% in the 4th quarter. Private Capital Group LLC now owns 739 shares of the company’s stock worth $28,000 after purchasing an additional 500 shares during the period. Sompo Japan Nipponkoa Asset Management CO. LTD. purchased a new position in shares of Dr.Reddy’s Laboratories during the 4th quarter valued at $236,000. Krane Funds Advisors LLC lifted its stake in shares of Dr.Reddy’s Laboratories by 18.4% during the 3rd quarter. Krane Funds Advisors LLC now owns 5,567 shares of the company’s stock valued at $420,000 after buying an additional 864 shares in the last quarter. Wedbush Securities Inc. purchased a new stake in Dr.Reddy’s Laboratories in the 3rd quarter worth $210,000. Finally, United Services Automobile Association purchased a new stake in Dr.Reddy’s Laboratories in the 3rd quarter worth $217,000. Institutional investors own 11.36% of the company’s stock.

NYSE:RDY opened at $37.42 on Thursday. The firm has a market capitalization of $6.32 billion, a PE ratio of 37.05 and a beta of 0.16. Dr.Reddy’s Laboratories Ltd has a 1-year low of $28.13 and a 1-year high of $40.20. The company has a current ratio of 1.81, a quick ratio of 1.26 and a debt-to-equity ratio of 0.18.

A number of analysts have recently weighed in on RDY shares. TheStreet upgraded shares of Dr.Reddy’s Laboratories from a “c+” rating to a “b” rating in a report on Friday, February 1st. CL King raised shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research report on Monday, February 4th. Citigroup cut shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, January 17th. Finally, Zacks Investment Research cut shares of Dr.Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, January 18th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $43.00.

WARNING: This story was published by Week Herald and is owned by of Week Herald. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://weekherald.com/2019/02/14/alps-advisors-inc-takes-position-in-dr-reddys-laboratories-ltd-rdy.html.

About Dr.Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Read More: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr.Reddy’s Laboratories Ltd (NYSE:RDY).

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply